Ketipinor

Quetiapine, the active ingredient in Ketipinor, is an atypical antipsychotic presented as an oral formulation for oral use. It is prescribed for schizophrenia, bipolar disorder and as adjunct therapy in major depressive disorder.

GNH USA supplies Ketipinor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine, an atypical antipsychotic, is used to manage several psychiatric conditions.

- Schizophrenia: reduces delusions, hallucinations and other psychotic symptoms. - Bipolar disorder: stabilises mood and diminishes manic or mixed episodes. - Major depressive disorder (adjunct therapy): enhances the effect of standard antidepressants when added to treatment.

Quetiapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to discomfort. - Constipation: infrequent or difficult bowel movements. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells increasing infection risk. - Prolonged QT interval: cardiac rhythm disturbance that may cause arrhythmia.

When prescribing quetiapine, several safety considerations should be observed.

- Pregnancy: use only if potential benefit justifies potential risk; consult a healthcare provider. - Breastfeeding: may be excreted in milk; decision should be made with professional guidance. - Elderly patients: increased sensitivity to sedation and orthostatic hypotension; monitor closely. - Hepatic impairment: dose adjustment may be required; assess liver function. - Concomitant CNS depressants: may enhance sedative effects; use caution. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and light.

Quetiapine can interact with other medicines; awareness of key interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - CNS depressants (e.g., alcohol, benzodiazepines): can cause excessive sedation or respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive orthostatic hypotension. - Anticholinergic agents: may worsen dry mouth and constipation. - Other antipsychotics: increased risk of QT prolongation.